MTOR and neoplasm: A more robust activity of novel dual PI3K/mTOR inhibitors, compared with either PI3K or mTOR inhibitors [43, 44], is required for the efficient suppression of tumor growth when multiple alterations of the PI3K pathway exist [45], in particular in the absence of functional PTEN.